By Associate Professor Suzanne Jean Hodgkinson

Journal articles

Nesbitt C; Sanfilippo P; Zhu C; Ozakbas S; Prat A; Girard M; Duquette P; Kalincik T; Roos I; Buzzard K; Skibina O; Foschi M; Surcinelli A; Lechner-Scott J; Patti F; Kermode AG; Fabis-Pedrini M; Carroll WM; Hodgkinson S; Grand’Maison F; Havrdova EK; Hradilek P; Habek M; Maimone D; Alroughani R; Vachova M; van Pesch V; Macdonell R; Spitaleri D; Khoury SJ; Gerlach O; de Gans K; McCombe P; Van Der Walt A; Butzkueven H; Jokubaitis V, 2026, 'Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study', Multiple Sclerosis Journal, 32, pp. 1083 - 1097, http://dx.doi.org/10.1177/13524585261460658

Zhu C; Vukusic S; Kalincik T; Mathey G; Kermode AG; Maillart E; Lechner-Scott J; Le Page E; Roos I; Ciron J; Kubala Havrdova E; Horakova D; De Sèze J; Skibina O; Ruet A; Yetkin MF; Labauge P; Habek M; Kwiatkowski A; Baghbanian SM; Zephir H; Meca-Lallana JE; Valero López G; Papeix C; Gerlach O; Defer G; Fabis-Pedrini M; Carroll WM; Lebrun-Frenay C; Hodgkinson S; Moreau T; Laureys G; Laplaud D-A; Prat A; Berger E; Lapointe E; Clavelou P; Ampapa R; Thouvenot E; Stetkarova I; Heinzlef O; Stourac P; Pelletier J; Foschi M; Al Khedr A; D'Amico E; Casez O; Alroughani R; Bourre B; Brecl Jakob G; Creange A; Ozakbas S; David T; John N; Magy L; Camdessanché J-P; Moulin S; Doghri I; Sarov Riviere M; Hankiewicz K; Pottier C; Manchon E; Aboab J; Tchikviladze M; Nifle C; Merlo D; Monif M; Zhou Z; Foong YC; Jokubaitis V; van der Walt A; Butzkueven H, 2026, 'Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.', Journal of Neurology Neurosurgery & Psychiatry, pp. jnnp-2026-339059, http://dx.doi.org/10.1136/jnnp-2026-339059

Roos I; Sharmin S; Ozakbas S; Alroughani R; Eichau S; Grand’Maison F; Boz C; Lechner-Scott J; Buzzard K; Prat A; Khoury SJ; Grammond P; van der Walt A; Blanco Y; Foschi M; Soysal A; Barnett M; Prevost J; Terzi M; Gerlach O; Macdonell R; Sa MJ; Spitaleri D; Laureys G; van Pesch V; John N; Cartechini E; Gouider R; Maimone D; Ramo-Tello C; Hodgkinson S; Slee M; McCombe P; Garber J; Sanchez-Menoyo JL; Al-Asmi A; Kermode AG; Lapointe E; Shaygannejad V; Van Wijmeersch B; Willekens B; Castillo-Triviño T; Taylor B; Mathey G; Le Page E; De Seze J; Ruet A; Clavelou P; Berger E; Zephir H; Kwiatkowski A; Pelletier J; Moreau T; Labauge P; Ciron J; Lebrun-Frenay C; Papeix C; Defer G; Laplaud DA; Thouvenot E; Stankoff B; Maillart E; Al-Khedr A; Bourre B; Casez O; Dos Santos A; Camdessanche JP; Hankiewicz K; Wahab A; Cabre P; Heinzlef O; Pottier C; Moulin S; Magy L; Labeyrie C; Doghri I; Vukusic S; Kalincik T, 2026, 'Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study', CNS Drugs, 40, pp. 1011 - 1025, http://dx.doi.org/10.1007/s40263-026-01287-8

Schmierer K; Wiendl H; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Sellebjerg F; Vermersch P; Jin H; Sponton L; Chudecka A; Bucello M; Gardner L; De Stefano N, 2026, 'A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study', Neurodegenerative Disease Management, ahead-of-print, pp. 1 - 11, http://dx.doi.org/10.1080/17582024.2026.2646302

Siriratnam P; Jokubaitis VG; Van Der Walt A; Sanfilippo PG; Zhu C; Etemadifar M; Altintas A; Al-Asmi A; Laureys G; Meca-Lallana JE; Foschi M; Alroughani R; Gomez-Figueroa E; Habek M; Khoury SJ; Simo M; Singhal BSG; Jakob GB; Fabis-Pedrini MJ; Soysal A; Kermode AG; Shaygannejad V; Kubala Havrdova E; Millan-Pascual J; Roos I; Mccombe PA; Nytrova P; Boz C; Surcinelli A; Kalincik T; Patti F; Huda S; Butzkueven H; Monif M; Ozakbas S; Kister I; Naser Moghadasi A; Boz C; Yamout B; Lechner Scott J; Carroll WM; Hardy TA; Vucic S; Reddel S; Ramanathan S; Grand'Maison F; Libertinova J; Hradilek P; Luis Sanchez Menoyo J; Ramo-Tello C; Rajda C; Al-Harbi T; Turkoglu R; Slee M; Willekens B; Vachova M; Houskova J; Mares M; Stetkarova I; Hodgkinson S; Buzzard K; Skibina O; Macdonell R; Lapointe E; Rous Z; Pavelek Z; Shalaby N; Karelis G; Alkhaboori J; Inshasi J; Boggild M; van Pesch V; Oh J; Recmanova E; Peterka M; Talaat F; Gray O; Csepany T; Mohammad Baghbanian S; D'Amico E; Skromne E; Yung Hor J; Fatih Yetkin M, 2026, 'Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder', Neurology, 106, http://dx.doi.org/10.1212/WNL.0000000000214707

Kalincik T; Sharmin S; Roos I; Freedman MS; Atkins H; Massey J; Sutton I; Withers B; Burman J; Torkildsen Ø; Bø L; Lehmann AK; Havrdova EK; Krasulova E; Trneny M; Kozak T; Macdonell R; Brown WJL; Coles A; van der Walt A; Butzkueven H; Van Wijmeersch B; Lechner-Scott J; Barnett M; Laureys G; Willekens B; Buzzard K; Skibina O; Gregorio MD; Hodgkinson S; Ozakbas S; Meca-Lallana JE; Alroughani R; Prevost J; Foschi M; Surcinelli A; Neri S; Eichau S; McCombe P; John N; Cárdenas-Robledo S; Oh J; Sanchez-Menoyo JL; Patti F; Gerlach O; Blanco Y; Grammond P; Sharrack B; Snowden JA, 2026, 'Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis', Brain, 149, pp. 951 - 962, http://dx.doi.org/10.1093/brain/awaf286

Al-atiyah R; Verma ND; Tran GT; Hodgkinson SJ; Hall BM, 2026, 'Cytokines Associated with Activation of CD4+CD25+Foxp3+ T Regulatory Cells', International Journal of Molecular Sciences, 27, http://dx.doi.org/10.3390/ijms27042085

Surcinelli A; Kalincik T; Roos I; D’Amico E; Lechner-Scott J; Ozakbas S; Hradilek P; Horáková D; Vachova M; Panzera I; Ruzza S; Piscaglia MG; Gerlach O; Meca-Lallana JE; Valero-López G; Kermode AG; Fabis-Pedrini MJ; Prevost J; Ampapa R; Hodgkinson S; Grand’Maison F; Khoury SJ; John NA; Peterka M; Houskova J; Recmanova E; Rous Z; Shaygannejad V; Alroughani R; Kuhle J; Jakob GB; Grammond P; Patti F; Van der Walt A; Butzkueven H; Foschi M, 2026, 'Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry', Therapeutic Advances in Neurological Disorders, 19, http://dx.doi.org/10.1177/17562864261430084

Roos I; Sharmin S; Horakova D; Kubala Havrdova E; Libertinova J; Vachova M; Alroughani R; Boz C; Rous Z; Buzzard K; Skibina O; Peterka M; Hradilek P; Mares M; Coles A; Brown JWL; Eichau Madueño S; Foschi M; Prevost J; Terzi M; Prat A; Girard M; Meca-Lallana JE; John N; Blanco Y; van der Walt A; Butzkueven H; Recmanova E; Laureys G; Ampapa R; Macdonell R; Pavelek Z; Khoury SJ; D’Amico E; Gerlach O; Van Pesch V; Maimone D; Romero-Ferrando B; McCombe PA; Mrabet S; Willekens B; Cárdenas-Robledo S; Ramo-Tello C; Stourac P; Houskova J; Shaygannejad V; Hodgkinson S; Cartechini E; Kermode AG; Fabis-Pedrini M; Carroll WM; Slee M; Sánchez-Menoyo JL; Al-Asmi A; Mathey G; Giannesini C; Michel L; Ciron J; De Sèze J; Ruet A; Kwiatkowski A; Zephir H; Papeix C; Lebrun-Frenay C; Moreau T; Berger E; Clavelou P; Pelletier J; Casez O; Bourre B; Wahab A; Magy L; Camdessanché JP; Doghri I; Tchikviladze M; Sellebjerg F; Romme Christensen J; Jensen HB; Illes Z; Bramow S; Rasmussen PV; Stilund ML; Schäfer J; Kant M; Weglewski A; Vukusic S; Magyari M; Laplaud DA; Kalincik T, 2026, 'Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study', Journal of Neurology Neurosurgery and Psychiatry, http://dx.doi.org/10.1136/jnnp-2026-338424

Kim HJ; Hodgkinson SJ; Ro LS; Situmeang RFV; Siritho S; Tan K; Nghia HTT; Viswanathan S; Alexander LYL; Loke H; Tay RJ; Taha K; Zeineddine M; Yamout B, 2026, 'Expert consensus on the clinical use of cladribine tablets for treating relapsing multiple sclerosis in the asia-pacific region', Multiple Sclerosis and Related Disorders, 105, http://dx.doi.org/10.1016/j.msard.2025.106897

De Stefano N; Vermersch P; Wiendl H; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Prat A; Leocani L; Schmierer K; Sellebjerg F; Nolting A; Petit C; Guala D; Sponton L; Gardner L; Hodgkinson S, 2026, 'Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study', Multiple Sclerosis Journal, http://dx.doi.org/10.1177/13524585261467624

Lizak N; Sharmin S; Horáková D; Havrdova EK; Eichau S; van der Walt A; Butzkueven H; Lechner-Scott J; Buzzard K; Skibina O; Gerlach O; Prat A; Girard M; Duquette P; Alroughani R; Patti F; Grand’Maison F; Sá MJ; Aguera-Morales E; Hodgkinson S; Grammond P; Kuhle J; Yamout B; Khoury SJ; Ozakbas S; Csepany T; John N; Laureys G; Terzi M; Amato MP; Boz C; Al-Asmi A; Cartechini E; Gouider R; Mrabet S; Roos I; Kalincik T, 2026, 'Managing reactivation of multiple sclerosis during treatment with natalizumab', Multiple Sclerosis Journal, 32, pp. 121 - 133, http://dx.doi.org/10.1177/13524585251398682

Wiendl H; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Jin H; Chudecka A; Kloetgen A; Lin D; Gardner L; De Stefano N, 2025, 'Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study', Video Journal of Biomedicine, 7, pp. 1 - 5, http://dx.doi.org/10.1080/vjbm-2025-0004

Ward K; Li V; Ramanathan S; Hall LA; Buzzard K; Young K; McKay F; Vigar V; Oishi S; San Martin LM; Kaskow B; Parnell G; Campbell JA; Sun J; Smith C; Jokubaitis V; Kalincik T; Tscharke D; Potter A; Brady E; Lechner-Scott J; Steinman L; Parmar M; Chataway J; Hardy T; Carroll WM; Barnett MH; Taylor BV; Broadley SA; Hodgkinson S; Butzkueven H; Khanna R; Kermode AG; Byrne S; van der Walt A; Riminton S; Pedrini M; Blum S; Trend S; Beadnall H; Ioannides Z; John N; Roos I; Ravindran J; Wang T; Kilpatrick TJ; Ponsonby AL; McCombe PA; Macdonell RAL; Phan T; Gaudieri S; Parratt JD; Bruestle A; Petratos S; Swaminathan S; Maltby V; Zhou Y; Monif M; Barton J; Asthana C; Giles L; Morahan J; Caswell N; Bar-Or A; Levy M; Giovannoni G, 2025, 'Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial', BMJ Neurology Open, 7, http://dx.doi.org/10.1136/bmjno-2025-001313

Roberts JI; Sharmin S; Horakova D; Kubala Havrdova E; Ozakbas, S; Lugaresi A; Tomassini V; Alroughani R; Buzzard K; Skibina O; Boz C; Turkoglu R; Maimone D; Yamout B; Khoury SJ; Spitaleri D; Lechner-Scott J; Girard M; Duquette P; Al-Asmi A; Ampapa R; Foschi M; Surcinelli A; Patti F; Van Pesch V; Ramo-Tello C; Sánchez-Menoyo JL; Altintas A; Grammond P; Cartechini E; Csepany T; Laureys G; Willekens B; Roos I; Kalincik T; Study Group M, 2025, 'Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years', Journal of Neurology Neurosurgery and Psychiatry, 96, pp. 1185 - 1193, http://dx.doi.org/10.1136/jnnp-2025-336343

Wiendl H; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Jin H; Chudecka A; Kloetgen A; Lin D; Gardner L; De Stefano N, 2025, 'Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study', Neurology and Therapy, 14, pp. 1743 - 1746, http://dx.doi.org/10.1007/s40120-025-00782-2

Shipley J; Beadnall HN; Sanfilippo PG; Yeh WZ; Horakova D; Havrdova EK; Hradilek P; Kalincik T; Roos I; Prat A; Girard M; Rous Z; Pavelek Z; Gerlach OHH; Lechner-Scott J; Alroughani R; Ozakbas S; Peterka M; Buzzard K; Skibina OG; Maimone D; Foschi M; Surcinelli A; Karabudak R; Spitaleri DLA; Lugaresi A; Tomassini V; Gouider R; Mrabet S; Ferrando BR; Hodgkinson S; Štourac P; Guimarães J; John NA; Macdonell RAL; Meca-Lallana JE; Butzkueven H; van der Walt A; Jokubaitis VG, 2025, 'Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability', JAMA Network Open, 8, pp. e2531581, http://dx.doi.org/10.1001/jamanetworkopen.2025.31581

Jokubaitis VG; Alroughani R; Altintas A; Eichau S; Hughes S; Willekens B; Horakova D; Havrdova EK; Ozakbas S; Boz C; Habek M; Kalincik T; Roos I; Etemadifar M; Peterka M; Lechner-Scott J; Meca-Lallana JE; Rous Z; Houskova J; Prat A; Girard M; Ampapa R; Buzzard K; Skibina O; John NA; Kermode AG; Fabis-Pedrini MJ; Foschi M; Surcinelli A; Blanco Y; Baghbanian SM; Gerlach O; Macdonell R; Pavelek Z; Stourac P; McCombe P; Laureys G; Butzkueven H; van der Walt A; Gray O; Vachova M; Libertinova J; Barnett M; Hradilek P; Duquette P; Martinkova A; Carroll WM; Recmanova E; Prevost J; Rath L; Izquierdo G; Moghadasi AN; Slee M; Maimone D; Oh J; Terzi M; Grammond P; Sanchez-Menoyo JL; D’Amico E; Ferrando BR; Yetkin MF; Yamout B; Stetkarova I; Ramo-Tello C; de Gans K; Gouider R; Mrabet S; Al-Asmi A; Karabudak R; Soysal A; Khoury SJ; Lapointe E; Cárdenas-Robledo S; Shalaby N; Spitaleri D; Guimarães J; Jakob GB; Hodgkinson S; Baghbanian M; Turkoglu R; van Pesch V; Grand’Maison F; Cartechini E; Gomez-Figueroa E; Massey J; Nohara C; Sakurai K; Mason D; Al-Harbi T; Castillo-Triviño T; Shimizu F; Taylor B; Hardy TA; Vucic S; Reddel S; Ramanathan S; Decoo D; de Vecino MCA; Nakamura Y; Chihara N, 2025, 'Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)', Multiple Sclerosis Journal, 31, pp. 1088 - 1101, http://dx.doi.org/10.1177/13524585251349125

Tran GT; Bedi S; Rakesh P; Verma ND; Carter N; Robinson CM; Al-Atiyah R; Hall BM; Hodgkinson SJ, 2025, 'Autoantigen and IL-2 activated CD4+CD25+T regulatory cells are induced to express CD8 and are autoantigen specific in inhibiting experimental autoimmune encephalomyelitis', Journal of Neuroimmunology, 404, http://dx.doi.org/10.1016/j.jneuroim.2025.578611

Verma ND; Al-atiyah R; Rakesh P; Lam AD; Chiu C; Tran GT; Hall BM; Hodgkinson SJ, 2025, 'Frequency and stability of populations of CD4+ and CD4+CD25+Foxp3+CD127lo Treg in healthy adults defined by cytometry using monoclonal antibodies to T cell associated molecules', Cytometry Part B Clinical Cytometry, 108, pp. 282 - 298, http://dx.doi.org/10.1002/cyto.b.22241

Pidugun V; Wardman D; Thomas P; Badge H; Ji J; Chen C; Pham T; Cheung AK; Manning N; Blair C; Cappelen-Smith C; Lin L; Hodgkinson SJ; McDougall A; Parsons M; Cordato D, 2025, 'Time to endovascular thrombectomy for acute ischaemic stroke in language other than English (LOTE) communities in South-Western Sydney', BMJ Neurology Open, 7, http://dx.doi.org/10.1136/bmjno-2025-001114

Müller J; Sharmin S; Lorscheider J; Ozakbas S; Karabudak R; Horakova D; Weinstock-Guttman B; Shaygannejad V; Etemadifar M; Alroughani R; Patti F; Eichau S; Prat A; Lugaresi A; Tomassini V; Kermode AG; Amato MP; Turkoglu R; Altintas A; Buzzard K; Soysal A; Van Der Walt A; Butzkueven H; Blanco Y; Gerlach O; Khoury SJ; Barnett M; John N; Lechner-Scott J; Foschi M; Surcinelli A; Van Pesch V; Prevost J; Sa MJ; Maimone D; D'Hooghe M; Hughes S; Hodgkinson S; Mcguigan C; Cartechini E; Taylor B; Spitaleri D; Slee M; Mccombe P; Yamout B; Benkert P; Kuhle J; Kappos L; Roos I; Kalincik T; Havrdova EK; Girard M; Duquette P; Fabis-Pedrini M; Carroll WM; Skibina O; Gouider R; Mrabet S; Ramo-Tello C; Solaro C; Habek M; Van Wijmeersch B; Ampapa R; Macdonell R; Oreja-Guevara C; De Gans K; Laureys G; Oh J; Garber J; Gray O; Agüera-Morales E; Sanchez-Menoyo JL; Castillo-Triviño T; Grigoriadis N; Petersen T; Hardy TA; Vucic S; Reddel S; Ramanathan S; Al-Asmi A; Simu M; Baghbanian SM; Poehlau D; Al-Harbi T; Rojas JI; Deri N; Lalive P; Cambron M; Csepany T; Shuey N; Willekens B; Shaw C; Decoo D; Massey J; Yaldizli Ö; Derfuss T; Granziera C, 2025, 'Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis', JAMA Neurology, 82, pp. 614 - 625, http://dx.doi.org/10.1001/jamaneurol.2025.0495

Toscano S; Spelman T; Ozakbas S; Alroughani R; Chisari CG; Lo Fermo S; Prat A; Girard M; Duquette P; Izquierdo G; Eichau S; Grammond P; Boz C; Kalincik T; Blanco Y; Buzzard K; Skibina O; Sa MJ; van der Walt A; Butzkueven H; Terzi M; Gerlach O; Grand'Maison F; Foschi M; Surcinelli A; Barnett M; Lugaresi A; Onofrj M; Yamout B; Khoury SJ; Prevost J; Lechner-Scott J; Maimone D; Amato MP; Spitaleri D; Van Pesch V; Macdonell R; Cartechini E; de Gans K; Slee M; Castillo-Triviño T; Soysal A; Sanchez-Menoyo JL; Laureys G; Van Hijfte L; McCombe P; Altintas A; Weinstock-Guttman B; Aguera-Morales E; Etemadifar M; Ramo-Tello C; John N; Turkoglu R; Hodgkinson S; Besora S; Van Wijmeersch B; Fernandez-Bolaños R; Patti F, 2025, 'First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis', Neurotherapeutics, 22, http://dx.doi.org/10.1016/j.neurot.2025.e00552

Li V; McKay FC; Tscharke DC; Smith C; Khanna R; Lechner-Scott J; Rawlinson WD; Lloyd AR; Taylor BV; Morahan JM; Steinman L; Giovannoni G; Bar-Or A; Levy M; Drosu N; Potter A; Caswell N; Smith L; Brady EC; Frost B; Hodgkinson S; Hardy TA; Broadley SA, 2025, 'Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach', CNS Drugs, 39, pp. 305 - 320, http://dx.doi.org/10.1007/s40263-024-01153-5

Campbell JA; Henson GJ; Ngwa VF; Ahmad H; Taylor BV; van der Mei I; Ramanathan S; Hardy TA; Shaw C; Garber J; Macdonell R; McCombe P; John N; Hodgkinson S; van der Walt A; Lechner-Scott J; Roos I; Kalincik T; Carroll WM; Fabis-Pedrini M; Kermode AG; Butzkueven H; Palmer AJ, 2025, 'Correction to: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications (PharmacoEconomics, (2025), 43, 2, (223-239), 10.1007/s40273-024-01417-4)', Pharmacoeconomics, 43, pp. 241, http://dx.doi.org/10.1007/s40273-024-01461-0

Campbell JA; Henson GJ; Ngwa VF; Ahmad H; Taylor BV; van der Mei I; Ramanathan S; Hardy TA; Shaw C; Garber J; Macdonell R; McCombe P; John N; Hodgkinson S; Walt AVD; Lechner-Scott J; Roos I; Kalincik T; Carroll WM; Fabis-Pedrini M; Kermode AG; Butzkueven H; Palmer AJ, 2025, 'Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications', Pharmacoeconomics, 43, pp. 223 - 239, http://dx.doi.org/10.1007/s40273-024-01417-4

Wiendl H; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Jin H; Chudecka A; Kloetgen A; Lin D; Gardner L; De Stefano N, 2025, 'Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study', Frontiers in Immunology, 16, http://dx.doi.org/10.3389/fimmu.2025.1512189

Schmierer K; Wiendl H; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Sellebjerg F; Vermersch P; Jin H; Sponton L; Chudecka A; Gardner L; De Stefano N, 2025, 'Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study', Therapeutic Advances in Neurological Disorders, 18, http://dx.doi.org/10.1177/17562864251351760

Wiendl H; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Jin H; Chudecka A; Kloetgen A; Lin D; Gardner L; De Stefano N, 2025, 'Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study (Frontiers in Immunology, (2025), 16, (1512189), 10.3389/fimmu.2025.1512189)', Frontiers in Immunology, 16, http://dx.doi.org/10.3389/fimmu.2025.1571978

Foong YC; Merlo D; Gresle M; Buzzard K; Horakova D; Havrdova EK; Kalincik T; Roos I; Hodgkinson S; Lechner-Scott J; Lugaresi A; Weinstock-Guttman B; Ozakbas S; Surcinelli A; Foschi M; Boz C; Khoury SJ; Yamout B; Laureys G; Blanco Y; Skibina O; Kuhle J; John N; Alroughani R; Prevost J; Van Pesch V; Tomassini V; Prat A; Girard M; Terzi M; Shaygannejad V; Ampapa R; Gray O; Etemadifar M; Guimarães J; Mccombe PA; Gerlach O; Solaro C; Butzkueven H; Zhu C; Van Der Walt A; Study Group M, 2025, 'Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis', Journal of Neurology Neurosurgery and Psychiatry, http://dx.doi.org/10.1136/jnnp-2025-336513

Siriratnam P; Sanfilippo P; van der Walt A; Sharmin S; Foong YC; Yeh WZ; Zhu C; Khoury SJ; Csepany T; Willekens B; Etemadifar M; Ozakbas S; Nytrova P; Altintas A; Al-Asmi A; Yamout B; Laureys G; Patti F; Simo M; Surcinelli A; Foschi M; McCombe PA; Alroughani R; Sánchez-Menoyo JL; Turkoglu R; Soysal A; Scott JL; Kalincik T; Butzkueven H; Jokubaitis V; Huda S; Monif M; Horakova D; Hijfte LV; Boz C; Shalaby N; Grand'Maison F; Mario ; Habek ; Singhal B; Hodgkinson S; Buzzard K; Skibina O; Slee M; Alkhaboori J; Inshasi J; Lapointe E; Boggild M; Vucic S; Gray O; Khurana D; Amato MP; Cristiano E; Liu Y; Cartechini E; Al-Harbi T; Hardy T, 2025, 'Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study', Journal of Neurology Neurosurgery and Psychiatry, 96, pp. 361 - 369, http://dx.doi.org/10.1136/jnnp-2024-334090

De Stefano N; Vermersch P; Wiendl H; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Prat A; Leocani L; Schmierer K; Sellebjerg F; Lehn A; Smyk A; Nolting A; Koelbach R; Hodgkinson S, 2025, 'Efficacité à long terme de la Cladribine comprimé (CladT) sur 4ans dans la sclérose en plaques récurrente (SEP R) : résultats de l’étude d’extension MAGNIFY-MS', Revue Neurologique, 181, pp. s145, http://dx.doi.org/10.1016/j.neurol.2025.01.282

Rakesh P; Zohorowska B; Diep J; Cheung J; Wu P; Al-Atiyah R; Suranyi M; Spicer T; Wong J; Tran GT; Hodgkinson SJ; Hall B; Verma ND, 2025, 'Expression of T Regulatory Cell Effector Molecules, CD39, HLA-DR and PD-1 in Renal Transplant Patients with Long Surviving Graft, Not Different to Healthy Volunteers', AMERICAN JOURNAL OF TRANSPLANTATION, 25

Al-atiyah R; Verma ND; Tran GT; Carter N; Hodgkinson SJ; Hall B, 2025, 'Human CD4+CD25+CD127lo Treg Have Enhanced Expression of IL-12Rb1 Upon Activation with Alloantigen and rIL-2', AMERICAN JOURNAL OF TRANSPLANTATION, 25

Rakesh P; Zohorowska B; Diep J; Cheung J; Wu P; Al-Atiyah R; Suranyi M; Spicer T; Wong J; Tran GT; Hodgkinson SJ; Hall B; Verma ND, 2025, 'T Regulatory Cell Phenotypes in Renal Transplant Patients with Long Surviving Graft: Increased Th2-Like Treg and Reduced Th1-and Th17-Like Treg', AMERICAN JOURNAL OF TRANSPLANTATION, 25

Yeh WZ; Van Der Walt A; Skibina OG; Kalincik T; Alroughani R; Kermode AG; Fabis-Pedrini MJ; Carroll WM; Lechner-Scott J; Boz C; Ozakbas S; Buzzard K; Habek M; John NA; Prat A; Girard M; Duquette P; Baghbanian SM; Hodgkinson S; Van Pesch V; Laureys G; Willekens B; Prevost J; Foschi M; De Gans K; Horakova D; Havrdova EK; Karabudak R; Patti F; McCombe PA; Maimone D; Altintas A; Ampapa R; Spitaleri D; Gerlach OHH; Sa MJ; Hughes S; Gouider R; Mrabet S; MacDonell RA; Turkoglu R; Cartechini E; Al-Asmi A; Soysal A; Oh J; Muros-Le Rouzic E; Guye S; Pasquarelli N; Butzkueven H; Jokubaitis VG; Barnett M; Slee M; Van Hijfte L; Yamout B; Terzi M; Blanco Y; Grammond P; Izquierdo G; Besora S; Taylor B; Castillo-Triviño T; Sanchez-Menoyo JL; Lugaresi A; Amato MP; Hardy T; Decoo D; Fragoso Y; Iuliano G; Gray O; Saladino ML; Grand'Maison F; Sempere AP; Shaw C; Van Wijmeersch B; Csepany T; Solaro C; Alkhaboori J; Garber J; Dominguez JA; Piroska I; McGuigan C; Cauchi M; Skromne E; Treviño-Frenk I; Mason D; Sirbu CA; Etemadifar M; Nohara C; Cambron M; De Vecino MCA; Shalaby N; Field D; Aguera-Morales E; Khurana D; Matsumoto R; Shimizu F; Sinnige LGF; Cárdenas-Robledo S, 2024, 'Disease Activity in Pregnant and Postpartum Women with Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies', Neurology Neuroimmunology and Neuroinflammation, 11, http://dx.doi.org/10.1212/NXI.0000000000200328

Lal AP; Foong YC; Sanfilippo PG; Spelman T; Rath L; Levitz D; Fabis-Pedrini M; Foschi M; Habek M; Kalincik T; Roos I; Lechner-Scott J; John N; Soysal A; D’Amico E; Gouider R; Mrabet S; Gross-Paju K; Cárdenas-Robledo S; Moghadasi AN; Sa MJ; Gray O; Oh J; Reddel S; Ramanathan S; Al-Harbi T; Altintas A; Hardy TA; Ozakbas S; Alroughani R; Kermode AG; Surcinelli A; Laureys G; Eichau S; Prat A; Girard M; Duquette P; Hodgkinson S; Ramo-Tello C; Maimone D; McCombe P; Spitaleri D; Sanchez-Menoyo JL; Yetkin MF; Baghbanian SM; Karabudak R; Al-Asmi A; Jakob GB; Khoury SJ; Etemadifar M; van Pesch V; Buzzard K; Taylor B; Butzkueven H; Van der Walt A, 2024, 'A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic', Journal of Neurology, 271, pp. 5813 - 5824, http://dx.doi.org/10.1007/s00415-024-12518-7

Roos I; Sharmin S; Malpas C; Ozakbas S; Lechner-Scott J; Hodgkinson S; Alroughani R; Eichau Madueño S; Boz C; van der Walt A; Butzkueven H; Buzzard K; Skibina O; Foschi M; Grand’Maison F; John N; Grammond P; Terzi M; Prévost J; Barnett M; Laureys G; Van Hijfte L; Luis Sanchez-Menoyo J; Blanco Y; Oh J; McCombe P; Ramo Tello C; Soysal A; Prat A; Duquette P; Yamout BI; Khoury S; van Pesch V; Macdonell R; José Sá M; Slee M; Kuhle J; Maimone D; Spitaleri DLA; Willekens B; Asmi AA; Tallantyre E; Robertson NP; Coles A; L Brown JW; Kalincik T, 2024, 'Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis', Multiple Sclerosis Journal, 30, pp. 1163 - 1175, http://dx.doi.org/10.1177/13524585241267211

De Brouwer E; Becker T; Werthen-Brabants L; Dewulf P; Iliadis D; Dekeyser C; Laureys G; Van Wijmeersch B; Popescu V; Dhaene T; Deschrijver D; Waegeman W; De Baets B; Stock M; Horakova D; Patti F; Izquierdo G; Eichau S; Girard M; Prat A; Lugaresi A; Grammond P; Kalincik T; Alroughani R; Grand’Maison F; Skibina O; Terzi M; Lechner-Scott J; Gerlach O; Khoury SJ; Cartechini E; Van Pesch V; Sà MJ; Weinstock-Guttman B; Blanco Y; Ampapa R; Spitaleri D; Solaro C; Maimone D; Soysal A; Iuliano G; Gouider R; Castillo-Triviño T; Sánchez-Menoyo JL; van der Walt A; Oh J; Aguera-Morales E; Altintas A; Al-Asmi A; de Gans K; Fragoso Y; Csepany T; Hodgkinson S; Deri N; Al-Harbi T; Taylor B; Gray O; Lalive P; Rozsa C; McGuigan C; Kermode A; Sempere AP; Mihaela S; Simo M; Hardy T; Decoo D; Hughes S; Grigoriadis N; Sas A; Vella N; Moreau Y; Peeters L, 2024, 'Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study', Plos Digital Health, 3, http://dx.doi.org/10.1371/journal.pdig.0000533

Alysha D; Blair C; Thomas P; Pham T; Nguyen T; Cordato TR; Badge H; Chappelow N; Lin L; Edwards L; Thomas J; Hodgkinson S; Cappelen-Smith C; McDougall A; Cordato DJ; Parsons M, 2024, 'Comparative Prevalence of Cerebrovascular Disease in Vietnamese Communities in South-Western Sydney', Journal of Cardiovascular Development and Disease, 11, http://dx.doi.org/10.3390/jcdd11060164

Spelman T; Herring WL; Acosta C; Hyde R; Jokubaitis VG; Pucci E; Lugaresi A; Laureys G; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Ozakbas S; Alroughani R; Kalincik T; Duquette P; Girard M; Petersen T; Patti F; Csepany T; Granella F; Grand’Maison F; Ferraro D; Karabudak R; Jose Sa M; Trojano M; van Pesch V; Van Wijmeersch B; Cartechini E; McCombe P; Gerlach O; Spitaleri D; Rozsa C; Hodgkinson S; Bergamaschi R; Gouider R; Soysal A; Castillo-Triviño ; Prevost J; Garber J; de Gans K; Ampapa R; Simo M; Sanchez-Menoyo JL; Iuliano G; Sas A; van der Walt A; John N; Gray O; Hughes S; De Luca G; Onofrj M; Buzzard K; Skibina O; Terzi M; Slee M; Solaro C; Oreja-Guevara ; Ramo-Tello C; Fragoso Y; Shaygannejad V; Moore F; Rajda C; Aguera Morales E; Butzkueven H, 2024, 'Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom', Journal of Medical Economics, 27, pp. 109 - 125, http://dx.doi.org/10.1080/13696998.2023.2293379

Hardy TA; Aouad P; Barnett MH; Blum S; Broadley S; Carroll WM; Crimmins D; Griffiths D; Hodgkinson S; Lechner-Scott J; Lee A; Malhotra R; McCombe P; Parratt J; Plummer C; Van der Walt A; Martel K; Walker RA, 2024, 'Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme', Multiple Sclerosis Journal Experimental Translational and Clinical, 10, http://dx.doi.org/10.1177/20552173231226106

De Stefano N; Wiendl H; Barkhof F; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Petit C; Gardner L; Montalban X, 2024, '160. Low Rate of Progression Independent of Relapse Activity (PIRA) in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets', Multiple Sclerosis and Related Disorders, 92, pp. 106121, http://dx.doi.org/10.1016/j.msard.2024.106121

De Stefano N; Vermersch P; Wiendl H; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Prat A; Leocani L; Schmierer K; Sellebjerg F; Lehn A; Smyk A; Nolting A; Koelbach R; Hodgkinson S, 2024, '162. Long-term Effectiveness of Cladribine Tablets over 4 years in Relapsing Multiple Sclerosis: Results from the MAGNIFY-MS Extension Study', Multiple Sclerosis and Related Disorders, 92, pp. 106123, http://dx.doi.org/10.1016/j.msard.2024.106123

Diouf I; Malpas CB; Sharmin S; Roos I; Horakova D; Kubala Havrdova E; Patti F; Shaygannejad V; Ozakbas S; Eichau S; Onofrj M; Lugaresi A; Alroughani R; Prat A; Duquette P; Terzi M; Boz C; Grand'maison F; Sola P; Ferraro D; Grammond P; Yamout B; Altintas A; Gerlach O; Lechner-Scott J; Bergamaschi R; Karabudak R; Iuliano G; McGuigan C; Cartechini E; Hughes S; Sa MJ; Solaro C; Kappos L; Hodgkinson S; Slee M; Granella F; De Gans K; McCombe PA; Ampapa R; Van Der Walt A; Butzkueven H; Sánchez-Menoyo JL; Vucic S; Laureys G; Sidhom Y; Gouider R; Castillo-Trivino T; Gray O; Aguera-Morales E; Al-Asmi A; Shaw C; Al-Harbi TM; Csepany T; Sempere AP; Treviño Frenk I; Stuart EA; Kalincik T, 2023, 'Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: Causal inference to emulate a multiarm randomised trial', Journal of Neurology Neurosurgery and Psychiatry, 94, pp. 1004 - 1011, http://dx.doi.org/10.1136/jnnp-2023-331499

Sharmin S; Roos I; Simpson-Yap S; Malpas C; Sánchez MM; Ozakbas S; Horakova D; Havrdova EK; Patti F; Alroughani R; Izquierdo G; Eichau S; Boz C; Zakaria M; Onofrj M; Lugaresi A; Weinstock-Guttman B; Prat A; Girard M; Duquette P; Terzi M; Amato MP; Karabudak R; Grand’Maison F; Khoury SJ; Grammond P; Lechner-Scott J; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Turkoglu R; Altintas A; Maimone D; Kermode A; Shalaby N; Pesch VV; Butler E; Sidhom Y; Gouider R; Mrabet S; Gerlach O; Soysal A; Barnett M; Kuhle J; Hughes S; Sa MJ; Hodgkinson S; Oreja-Guevara C; Ampapa R; Petersen T; Ramo-Tello C; Spitaleri D; McCombe P; Taylor B; Prevost J; Foschi M; Slee M; McGuigan C; Laureys G; Hijfte LV; de Gans K; Solaro C; Oh J; Macdonell R; Aguera-Morales E; Singhal B; Gray O; Garber J; Wijmeersch BV; Simu M; Castillo-Triviño T; Sanchez-Menoyo JL; Khurana D; Al-Asmi A; Al-Harbi T; Deri N; Fragoso Y; Lalive PH; Sinnige LGF; Shaw C; Shuey N; Csepany T; Sempere AP; Moore F; Decoo D; Willekens B; Gobbi C; Massey J; Hardy T; Parratt J; Kalincik T, 2023, 'The risk of secondary progressive multiple sclerosis is geographically determined but modifiable', Brain, 146, pp. 4633 - 4644, http://dx.doi.org/10.1093/brain/awad218

Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Der Walt AV; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Morgado YB; Spitaleri DLA; Pesch VV; Horakova D; Ampapa R; Patti F; MacDonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H, 2023, 'A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry', Neurodegenerative Disease Management, 13, pp. 215 - 221, http://dx.doi.org/10.2217/nmt-2023-0005

Kalincik T; Sharmin S; Roos I; Freedman MS; Atkins H; Burman J; Massey J; Sutton I; Withers B; MacDonell R; Grigg A; Torkildsen Ø; Bo L; Lehmann AK; Havrdova EK; Krasulova E; Trněný M; Kozak T; Van Der Walt A; Butzkueven H; McCombe P; Skibina O; Lechner-Scott J; Willekens B; Cartechini E; Ozakbas S; Alroughani R; Kuhle J; Patti F; Duquette P; Lugaresi A; Khoury SJ; Slee M; Turkoglu R; Hodgkinson S; John N; Maimone D; Sa MJ; Van Pesch V; Gerlach O; Laureys G; Van Hijfte L; Karabudak R; Spitaleri D; Csepany T; Gouider R; Castillo-Triviño T; Taylor B; Sharrack B; Snowden JA; Mrabet S; Garber J; Sanchez-Menoyo JL; Aguera-Morales E; Blanco Y; Al-Asmi A; Weinstock-Guttman B; Fragoso Y; De Gans K; Kermode A, 2023, 'Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis', JAMA Neurology, 80, pp. 702 - 713, http://dx.doi.org/10.1001/jamaneurol.2023.1184

Zhu C; Kalincik T; Horakova D; Zhou Z; Buzzard K; Skibina O; Alroughani R; Izquierdo G; Eichau S; Kuhle J; Patti F; Grand'maison F; Hodgkinson S; Grammond P; Lechner-Scott J; Butler E; Prat A; Girard M; Duquette P; MacDonell RAL; Weinstock-Guttman B; Ozakbas S; Slee M; Sa MJ; Van Pesch V; Barnett M; Van Wijmeersch B; Gerlach O; Prevost J; Terzi M; Boz C; Laureys G; Van Hijfte L; Kermode AG; Garber J; Yamout B; Khoury SJ; Merlo D; Monif M; Jokubaitis V; Van Der Walt A; Butzkueven H, 2023, 'Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation', JAMA Neurology, 80, pp. 739 - 748, http://dx.doi.org/10.1001/jamaneurol.2023.1542

Daruwalla C; Shaygannejad V; Ozakbas S; Havrdova EK; Horakova D; Alroughani R; Boz C; Patti F; Onofrj M; Lugaresi A; Eichau S; Girard M; Prat A; Duquette P; Yamout B; Khoury SJ; Sajedi SA; Turkoglu R; Altintas A; Skibina O; Buzzard K; Grammond P; Karabudak R; van der Walt A; Butzkueven H; Maimone D; Lechner-Scott J; Soysal A; John N; Prevost J; Spitaleri D; Ramo-Tello C; Gerlach O; Iuliano G; Foschi M; Ampapa R; van Pesch V; Barnett M; Shalaby N; D’hooghe M; Kuhle J; Sa MJ; Fabis-Pedrini M; Kermode A; Mrabet S; Gouider R; Hodgkinson S; Laureys G; Van Hijfte L; Macdonell R; Oreja-Guevara C; Cristiano E; McCombe P; Sanchez-Menoyo JL; Singhal B; Blanco Y; Hughes S; Garber J; Solaro C; McGuigan C; Taylor B; de Gans K; Habek M; Al-Asmi A; Mihaela S; Castillo Triviño T; Al-Harbi T; Rojas JI; Gray O; Khurana D; Van Wijmeersch B; Grigoriadis N; Inshasi J; Oh J; Aguera-Morales E; Fragoso Y; Moore F; Shaw C; Baghbanian SM; Shuey N; Willekens B; Hardy TA; Decoo D; sempere AP; Field D; Wynford-Thomas R; Cunniffe NG; Roos I; Malpas CB; Coles AJ; Kalincik T; Brown JWL, 2023, 'Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis', Multiple Sclerosis Journal, 29, pp. 875 - 883, http://dx.doi.org/10.1177/13524585231151951

Back to profile page